Trials / Completed
CompletedNCT05172180
Correction of Metabolic Disorders and Its Effect on Respiratory Function of Lungs in Patients With Severe COVID-19
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 105 (actual)
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Objective of the study: to investigate the effect of meglumine succinate solution on the dynamics of metabolic blood parameters and respiratory function of the lungs in intensive care patients with new coronavirus infection. An observational prospective study included 105 patients with a severe course of novel coronavirus infection
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Reamberin | the balanced succinate-containing crystalloid solution Reamberin (meglumine sodium succinate) |
| DRUG | Ringer's solution | Ringer's solution at an average daily dose of 8.1 ml/kg/day |
Timeline
- Start date
- 2020-12-01
- Primary completion
- 2021-01-31
- Completion
- 2021-04-01
- First posted
- 2021-12-29
- Last updated
- 2024-12-19
Locations
1 site across 1 country: Russia
Source: ClinicalTrials.gov record NCT05172180. Inclusion in this directory is not an endorsement.